INS and hepatocellular carcinoma: When we performed stratified analyses by age (≥65 years), diabetes duration (≥4.4 years), type of chronic viral hepatitis (CHB or CHC), presence of cirrhosis, and type of concurrent diabetes medication (metformin, DPP4i, TZD, or insulin), the decreased risk of liver-related events, including HCC, in the SGLT2i group was generally consistent regardless of the baseline characteristics with an sHR of 0.74 (95% CI, 0.65–0.85; p < 0.001).